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   bjective: This study evaluated the bioavailability of fluoride after topical application of a dual-fluoride varnish commercially
available in Brazil, when compared to Duraphat™. Material and methods: The urinary fluoride output was evaluated in seven 5-
year-old children after application of the fluoride varnishes, in two different phases. In the first phase (I), children received topical
application of the fluoride varnish Duofluorid XII (2.92% fluorine, calcium fluoride + 2.71% fluorine, sodium fluoride, FGM™).
After 1-month interval (phase II), the same amount (0.2 mL) of the fluoride varnish Duraphat (2.26% fluorine, sodium fluoride,
Colgate™) was applied. Before each application all the volunteers brushed their teeth with placebo dentifrice for 7 days. Urinary
collections were carried out 24 h prior up to 48 h after the applications. Fluoride intake from the diet was also estimated. Fluoride
concentration in diet samples and urine was analyzed with the fluoride ion-specific electrode and a miniature calomel reference
electrode coupled to a potentiometer. Data were tested by ANOVA and Tukey’s post hoc test (p<0.05). Results: There were significant
differences in the urinary fluoride output between phases I and II. The use of Duofluorid XII did not significantly increase the
urinary fluoride output, when compared to baseline levels. The application of Duraphat caused a transitory increase in the urinary
fluoride output, returning to baseline levels 48 h after its use. Conclusions: The tested varnish formulation, which has been shown
to be effective in in vitro studies, also can be considered safe.
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INTRODUCTION
Fluoride has been considered an effective anti-caries agent
when delivered in many vehicles and concentrations, including
a variety of professionally applied fluoride products14. Among
these products, the use of fluoride varnishes has the advantage
of increasing the contact time between fluoride and the tooth
surfaces, which improves fluoride uptake by enamel2,9.
However, some of the product is ingested during placement,
despite the rapid setting time and the small dosage used.
Duraphat, containing 2.26% fluorine (or 5% sodium fluoride),
is probably the most commonly used4,6. Pessan, et al.8
demonstrated that, when fluoride varnish Duraphat was used
in 4-7 year-old children, a transitory significant increase in
the urinary fluoride output was detected, returning to baseline
levels in the last 24 h. Thus, the product can be regarded as
safe.
Since 1998, a dual-fluoride varnish manufactured in Brazil
has been available in the market (Duofluorid XII, FGM™).
The product has a lower cost and has been proved to be
effective for caries control in vitro3. However, it has a higher
fluoride content (2.92% fluorine, calcium fluoride + 2.71%
fluorine, sodium fluoride) when compared to a widespread
used fluoride varnish (Duraphat, Colgate), which prompted
us to investigate its fluoride bioavailability after topical
application in children. Considering that the urine is the main
excretion route for ingested fluoride13, urinary fluoride
excretion was used to assess the fluoride bioavailability.
MATERIAL AND METHODS
Seven children aged 5 years old (± 6 months, 3 males and
4 females) took part in this study. Children were selected at
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the Pediatric Dentistry Clinic from Bauru Dental School,
University of São Paulo. All the children lived in a fluoridated
area (Bauru, SP, Brazil, 0.6-0.8 mg fluoride/L in the drinking
water), had good oral health and were not using medicines.
Children that had focal infections, residual roots or many
cavitated lesions did not participate. The protocol of the study
was reviewed and approved by the Institutional Review Board
(IRB) of the Bauru School of Dentistry, University of São
Paulo. The aims of the study were explained verbally and in
writing to the parents who signed an IRB-approved informed
consent document.
Study Protocol
The study had two different experimental periods (phase
I and phase II). The children used a placebo dentifrice (without
fluoride) for 7 days before each phase. In phase I, the
volunteers received an application of the test fluoride varnish
(Duofluorid XII, FGM™), Joinville, SC, Brazil), based on
synthetic resin and ethanol as solvent, containing 6% calcium
fluoride and 6% sodium fluoride (5.63% fluorine). This
fluoride varnish has a transparent color, presenting the
advantage of not influencing the esthetic appearance. After a
washout period of 30 days, in phase II, the same children
received an application of the control fluoride varnish
(Duraphat, Colgate™, A. Nattermann GmbH, Germany)
based on colophony resin and containing 5% sodium fluoride
(2.26% fluorine), according to the manufacturer. It has a
yellowish-brown color and adheres to tooth surfaces for
several hours after application.
Before the applications, the teeth were thoroughly cleaned
with pumice, sprayed with water and air-dried. The varnish
was applied at 9 a.m., using a small brush and starting with
the interdental areas. All tooth surfaces were subsequently
covered. To facilitate the final setting of the varnish, the teeth
were carefully rinsed with water and this was sucked up. The
children were told to avoid solid foods during the first 4 h
following application and to refrain from brushing their teeth
until the next morning. Thus, the children only brushed their
teeth once in the day that the fluoride varnish was applied.
The amount of varnish used was 0.2 mL per child.
Urinary Sample Collections
Urine was collected during the 24 h period prior to the
use of fluoride varnish (control day) until 48 h thereafter, for
both phases.
The protocol for urinary collection described by Villa, et
al.11 was followed. Children were instructed to void their urine
only in their individual labeled wide-necked plastic vessels.
Urine sample collection (control day) started at 9:00 a.m.
and vessel 1, containing all the urine collected up to 9:00
p.m., was closed and brought to our laboratory, where the
volume of each individual sample was immediately
determined. An aliquot (50 mL) was frozen (-20ºC) until
fluoride analysis. Vessel 2 contained all individual urine
collected from 9:00 p.m. until 9:00 a.m. of the following (test)
day, when the application of fluoride varnish was carried out.
From then on, all individual urine voidings from each child
were collected following the same pattern as previously
described for the control day, for additional 48 h (vessels 3 to
6). All flasks containing urine samples were kept permanently
closed in a refrigerator until they were brought to the
laboratory.
Estimation of Fluoride Intake from Diet
In order to estimate the total fluoride intake of the children
at the experimental day, fluoride ingested from diet was
determined, and “duplicate-plate” samples of all foods and
beverages ingested during one day were collected, as
described by Guha-Chowdhurry, et al.5. The duplicate diets
were collected at the children’s houses. As the children
refrained from brushing their teeth after varnish application,
the estimation of fluoride ingested from dentifrice was not
necessary.
The parents were instructed not to offer their children hard
foods, in order to not remove the varnish in the 24 h after the
applications. The diet was duplicated as precisely as possible
by observing the amounts that the children had really eaten
and drunk.  Parents were requested to remove parts of foods
not normally eaten, such as seeds, cores, skin, and bones,
before including the food in the container.
Parents were asked to use household measures, such as
teaspoon, table spoon, or cupful, to approximate quantities
of food ingested. In the case of cooked meals, parents were
asked to serve 2 similar portions on 2 separate plates, to wait
until the children had finished their portion, and to add or
remove comparable portions on the separate plate.
The diet was homogenized using deionized water, the total
volume was measured and an aliquot sample of 50 mL was
taken and frozen (-20ºC) until analysis.
Fluoride Analysis
Fluoride analysis in the urine samples was determined
using an ion-specific electrode (Model 9609, Orion Research
Inc., Cambridge, MA, USA), after sample buffering with an
equal volume of TISAB II. Standards were prepared by serial
dilution of 100 ppm sodium fluoride stock solution (Orion
Research Inc., Beverly, MA, USA). The standard curve had
a coefficient correlation = 0.99. The mean repeatability of
the readings, based on duplicate samples, was 96%.
Fluoride concentrations in the diet samples were
determined after overnight hexamethyldisiloxane (HMDS)-
facilitated diffusion10 as modified by Whitford12 using the
fluoride ion-specific electrode (Orion 9409, Orion Research
Inc., Beverly, MA, USA) and a miniature calomel reference
electrode (Accumet, #13-620-79, Fisher Scientific, Pittsburgh,
PN, USA), coupled to a potentiometer (Orion Research Inc.,
model EA 940, Beverly, MA, USA). During the diffusion
process, which was conducted at room temperature, the
solutions in the non-wettable Petri dishes (Falcon, No. 1007,
Becton Dickinson Labware, Lincoln Park, NJ, USA) were
gently swirled on a rotatory shaker. Fluoride standards
(0.0095, 0.019, 0.095 and 0.190 μg fluoride) were prepared
by serial dilution of a stock solution of 0.1 M fluoride (Orion
Research Inc., 940906, Beverly, MA, USA) in triplicate and
diffused in the same manner as the samples. Comparison with
identical nondiffused fluoride standards showed that recovery
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after diffusion was > 99%. The standard curve had a
correlation coefficient = 0.99. All samples were analyzed in
duplicate.  The mean repeatability of the readings, based on
duplicate samples, was 90%.
Statistical Analysis
The software GraphPad Prism version 4.0 for Windows
(GraphPad Inc., La Jolla, CA, USA) was used. For analysis,
12-h urinary data were combined, so that 24-h data were
obtained.  Fluoride excreted in urine at the first 24 h (control
day) was compared with fluoride excreted 24 h (experimental
day) and 48 h thereafter using two-way repeated measures
ANOVA and Tukey´s post hoc test. The comparison of
fluoride intake from the diet in the two phases was made using
paired t test. The comparison of the urinary pHs among the
collection and between the phases was done using two-way
repeated measures ANOVA. A significance level of 5% was
adopted in all cases.
RESULTS
Table 1 and Figure 1 show, respectively, the individual
and mean amounts of fluoride excreted in urine in the control
day (baseline), as well as at the 24 and 48 h following the
application of the varnishes. As can be depicted from Table
1, the results showed a wide variation among the subjects for
each collection. For volunteers C and F, high baseline urinary
FIGURE 1- Means of the amount of fluoride excreted in urine before varnishes application, and after 24 h and 48 h. Bars indicate
standard error of means. * shows a significant difference from the other values (two-way repeated measures ANOVA, p<0.05)
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Children    Duofluorid XII Duraphat
codes 24 h before 24 h after 48 h after 24 h before 24 h after 48 h after
application application application application application application
A 0.186 0.260 0.150 0.284 0.471 0.186
B 0.240 0.456 0.225 0.266 0.907 0.260
C 0.381 0.267 0.209 0.434 0.674 0.155
D 0.255 0.499 0.480 0.299 0.435 0.458
E 0.233 0.578 0.366 0.244 0.631 0.270
F 0.490 0.190 0.248 0.188 0.818 0.255
G 0.186 0.290 0.257 0.240 0.447 0.227
Mean 0.282a 0.363a 0.276a 0.279a 0.626b 0.259a
Standard 0.113 0.146 0.111 0.077 0.187 0.097
Deviation
TABLE 1- Individual and mean amount of fluoride excreted (mg/day) in urine before and after application of Duofluorid XIITM
and DuraphatTM varnishes
Different letters indicate statistically significant difference (p<0.05).
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fluoride values were detected when Duofluorid XII was used
and no numerical increases were found after its application.
For all the other situations, increases in urinary fluoride were
detected 24 h after the varnishes were applied. When Duraphat
was used, a significant increase in mean urinary fluoride
excretion was observed (0.626±0.187 mg/day), returning to
baseline levels (0.279±0.077 mg/day) in the subsequent 24 h
(0.259±0.097 mg/day). As for Duofluorid XII, there was only
a slight increase in the mean amount of fluoride excreted after
the varnish was used (0.363±0.146 mg/day), which did not
differ from baseline (0.282±0.113 mg/day) and the subsequent
day (0.276±0.111 mg/day). In addition, the amount of fluoride
excreted in urine when Duraphat was used was significantly
higher when compared to Duofluorid XII.
Table 2 shows the values of fluoride intake (mg) from the
diet and pH values of the 6 urine samples collected, for each
volunteer, as well as the means. The mean fluoride intake
from diet (±SD) at phases I and II was 0.288±0.186 mg/day
and 0.214±0.112 mg/day, respectively. There was no
significant difference between the phases (t = 1.43, p = 0.203).
The mean pH of the samples (±SD) ranged between 6.1±0.7
and 6.9±0.4 for phase I and between 6.1±0.6 and 6.7±0.7 for
phase II. There was no significant difference among the
collections (F=2.207, p=0.075) or between the phases
(F=0.323, p=0.573).
DISCUSSION
Taking into account the toxicological aspect, regular
swallowing of low doses of fluoride from several sources by
small children has been associated with the development of
mild dental fluorosis7. In this context, a careful vigilance on
new fluoride products is necessary. Among these products,
Duofluorid XII (FGM™), a dual-fluoride varnish
manufactured in Brazil, has been available in the market. Its
efficacy has been demonstrated in in vitro studies using a
pH-cycling system3. This varnish has been shown to be as
effective as Duraphat to reduce demineralization of bovine
enamel blocks3. This, in addition to the low cost of the product,
could increase its use in private and public clinical practices.
Since Duraphat has 2.26% fluoride and Duofluorid XII has
5.63% fluoride, concern has been arisen regarding the
toxicological potential of this product, especially in children.
Twenty-four hour urinary fluoride excretion was chosen
as the response variable to evaluate the bioavailability of
fluoride from the products tested. This was done because the
kidneys are the major route for the excretion of fluoride12.
Since the volunteers used a fluoride-free dentifrice before
and during the study, and the amount of estimated fluoride
ingested from the diet was not significantly different between
the phases, any increase in the fluoride excreted in urine could
be attributed to the tested products.
In this study, significant differences in the mean urinary
fluoride excretion between the varnishes tested were found.
Duraphat produced a significant increase in urinary fluoride
output, which returned to baseline levels in the subsequent
24 h. Similar values (around 600 μg) have already been
described by Pessan, et al.8. Despite this transient increase,
Duraphat can be regarded as safe, because the baseline values
were rapidly reestablished both for the mean and individual
values. In addition, Baez, et al.1 suggested that urinary fluoride
excretion rates of 0.4-0.5 mg/day in children of 3-6 years
would be considered an indication of “optimal” fluoride
intake. One point that calls attention when Table 1 is observed
is that for volunteers C and F, when Duofluorid XII was used
it was not possible to detect a numerical increase in urinary
fluoride levels after 24 h. It is also noteworthy that for these
volunteers high baseline urinary fluoride levels were detected,
which may have led to this result. The high baseline fluoride
levels can be partially explained by the higher fluoride intake
in this day, especially for volunteer F (Table 2). The lower
Vol F intake Urine pH
from diet
1st  2nd  3rd 4th 5th 6th
   I    II   I   II   I   II   I   II   I   II   I   II   I   II
A 0.10 0.09 6.8 6.9 5.5 6.1 7.0 7.8 5.6 6.5 6.6 6.6 5.5 6.6
B 0.16 0.09 7.5 6.7 7.5 6.4 7.7 7.0 7.0 6.5 6.6 7.1 6.7 6.5
C 0.52 0.23 6.5 6.3 6.1 6.0 6.5 6.8 5.5 5.5 6.4 5.8 6.6 5.3
D 0.42 0.22 5.7 7.0 5.5 5.5 6.7 7.0 7.5 5.9 6.9 7.0 6.0 5.9
E 0.30 0.34 6.9 6.7 6.5 7.0 6.7 6.5 6.3 6.6 6.5 6.1 6.7 6.5
F 0.46 0.37 5.6 6.5 5.5 6.0 6.5 6.1 5.7 5.9 6.7 7.0 5.9 5.5
G 0.05 0.16 6.8 6.6 6.3 6.5 7.0 5.7 6.8 6.6 6.5 6.0 6.8 6.7
Mean 0.29 0.21 6.5 6.7 6.1 6.2 6.9 6.7 6.3 6.2 6.6 6.5 6.3 6.1
SD 0.19 0.11 0.7 0.2 0.7 0.5 0.4 0.7 0.8 0.4 0.2 0.5 0.5 0.6
TABLE 2- Fluoride intake (mg) from the diet and pH values of the 6 urine samples collected, for each volunteer (Vol) at phases
I (Duofluorid) and II (Duraphat)
The difference between phase I and phase II was not significant either for fluoride intake from diet or urinary pH (p>0.05).
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urinary pH observed for volunteers C and F at the 4th urinary
collection (Table 2) may help to explain the lower urinary
fluoride excretion observed for these volunteers 24 h after
the use of Duofluorid XII. This is due to the fact that when
the pH in the renal tubules is low, a higher amount of HF is
present. This molecule can readily cross the wall of the renal
tubules, returning to the systemic circulation, which decreases
the amount of  fluoride that would remain in the renal tubules
to be excreted in urine.12. Regardless the cause of this lower
urinary fluoride excretion, the lack of numeric increase in
urinary fluoride excretion after the application of Duofluorid
XII for these volunteers is, in a certain way, a confirmation of
the safety of this product.
As Duofluorid XII presents 2.45 times more fluoride than
Duraphat, it was expected to induce higher circulating fluoride
levels, which, in turn, would increase urinary fluoride
excretion. However, it caused only a slight increase in the
amount of fluoride excreted in urine (81 μg/day) and this
amount did not significantly differ from baseline. This
apparent discrepancy may be explained by a combination of
factors. First, the number of volunteers in each group might
have not been enough. This, however, does not seem to be
the reason since there was a significant increase in urinary
fluoride when Duraphat varnish was used. Second, the
possible complexation between fluoride and the synthetic resin
or the ethanol present in Duofluorid’s XII formulation may
have led to this result. Third, there could have been a higher
fluoride uptake by the body tissues, after the use of Duofluorid
XII, which does not seem to have occurred because the study
had a crossover protocol, with the same volunteers
participating in both phases. Fourth, the interactive effects
between calcium fluoride and sodium fluoride present in
Duofluorid XII assure that it promptly reacts with the teeth
surface, maximizing its anti-cariogenic effects, thus
minimizing the fluoride systemic bioavailability. Duofluorid
XII formulation has fluoride as calcium fluoride (6%) and
sodium fluoride (6%). According to the manufacturer, calcium
fluoride is added in order to increase the potential of calcium
fluoride formation on the teeth, by driving the reaction to the
precipitation on the teeth. In addition, the presence of calcium
fluoride in the varnish could avoid that the calcium fluoride
formed on the teeth migrate to the varnish, improving the
fluoride deposited on the teeth. This is consistent with the
fact that the application of Duofluorid XII in vitro led to a
higher surface microhardness of enamel blocks when
compared to Duraphat, despite this difference was not
significant3. Furthermore, despite Duofluorid XII contains a
higher fluoride amount, the quantity of fluoride that is soluble
in saliva may be similar to other varnishes like Duraphat,
because the amount of fluoride added as sodium fluoride is
almost the same.  If these assumptions are true, the addition
of calcium fluoride to topical application fluoride products
could be a good alternative to increase the delivery of fluoride
to enamel, without increasing the risk of toxicity of the product.
However, further investigation to support this assumption is
required.
CONCLUSIONS
The tested dual-fluoride varnish formulation is safe to be
used in children.
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